Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection

Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called “incretins” because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Avogaro, Angelo, de Kreutzenberg, Saula, Fadini, Gianpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030590/
https://www.ncbi.nlm.nih.gov/pubmed/23844811
http://dx.doi.org/10.2174/13816128113199990474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030590/
https://www.ncbi.nlm.nih.gov/pubmed/23844811
http://dx.doi.org/10.2174/13816128113199990474

Ejemplares similares